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use#LAAFor over 20 years p53 has been recognized as a tumor 
suppressor [1] that induces cell cycle arrest to allow for 
DNA damage repair or apoptosis of an irreparable cell. 
Germline mutations of p53 result in the clinical Li 
Fraumeni syndrome, characterized by high susceptibility 
to breast cancer, acute leukemias, sarcomas, brain tumors 
and adrenal cortical carcinoma [2]. Li Fraumeni syn  drome 
is rare, but somatic p53 mutations occur with a frequency 
of 15 to 20% in all breast cancers, and with higher 
frequency in tumors that carry a poor prognosis, such as 
high-grade and estrogen receptor-negative tumors [3].
While several hundred cancer-associated p53 muta-
tions have been identiﬁ  ed, the general pattern is that p53 
in cancer frequently carries missense mutations that 
allow for the expression of a mutant protein with 
defective DNA binding but an intact trans-activating 
domain. Th   is observation has led to the hypothesis that 
mutant p53 confers an advantage to cancer cell growth 
through a gain of function where the mutant protein is 
now targeted to DNA sites that encode a cancer-
promoting transcriptional program rather than a tumor 
suppressor program [4]. Th  e recent study by Girardini 
and colleagues [5] sheds light on the mechanism by 
which a mono-allelic missense mutation of p53 can turn 
an indispensable tumor suppressor into a potent 
oncogene aided by the prolyl isomerase Pin1.
Pin1 catalyzes conformational changes in a subset of 
mitotic phosphoproteins; via its WW domain, Pin1 will 
ﬁ  rst dock at the phosphorylated serine or threonine, and 
then Pin1’s prolyl isomerase domain will catalyze the 
‘switch’ of the adjacent proline residue from the cis to 
trans position relative to the protein’s carbon backbone 
[6]. Th   is conformational re-positioning of proline’s bulky 
5-carbonyl ring does not change the atomic composition 
of the target protein, but rather its three-dimensional 
structure. Th  us, the prolyl isomerase Pin1 adds an 
additional layer of complexity to mitotic signaling 
networks by regulating post-phosphorylational folding 
mechanisms that modulate the tertiary structure of a 
target protein. Th   e simple Pin1 binding motif, pSer/Th  r-
Pro [7], is often found multiple times in a given protein, 
and thus Pin1 activates a broad range of phosphoproteins 
involved in cell division. Th   e evolutionary intent of Pin1-
mediated prolyl isomerization appears to be the co-
ordination of pro-proliferative signals and cell cycle 
checkpoint regulators to ensure orderly progression 
through mitosis [8]. Th   is balancing function explains why 
Pin1 targets include proteins that facilitate cell cycle 
progression, such as cyclinD1 [9], as well as proteins that 
can halt mitosis, such as wild-type p53 [10-12]. Because 
of its simplicity, however, this mechanism is also blind to 
mutations in the target protein outside the Pin1 recog-
nition site, and, as Girardini and colleagues discovered, 
enables mutant p53 to subvert this powerful mechanism 
to enhance tumorigenesis.
Comparing tumor phenotypes in a mouse model of Li 
Fraumeni syndrome (p53 R172H mutation [13]) and the 
p53 null background, the authors found that it is the 
presence of the mutant p53, and not the absence of wild-
type p53, that promotes carcinogenesis, and that mutant 
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Mutation of p53 occurs in 15 to 20% of all breast 
cancers, and with higher frequency in estrogen-
receptor negative and high-grade tumors. Certain p53 
mutations contribute to malignant transformation 
not only through loss of wild-type p53 but also 
through a gain of function of specifi  c p53 mutations. 
How these hotspot mutations turn p53 from a tumor 
suppressor into an oncogene had until now remained 
incompletely understood. In an elegant paper 
published in the July 12 issue of Cancer Cell, Girardini 
and colleagues show how Pin1-mediated prolyl 
isomerization, a regulatory mechanism intended by 
evolution to support p53’s function as a guardian of 
the genome, can go haywire and accelerate malignant 
transformation when p53 carries a dominant-negative 
mutation.
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presence of Pin1. Th   e argument that Pin1 promotes the 
gain of function of mutant p53 is further strengthened by 
the fact that Pin1 enhanced carcinogenesis when only a 
mono-allelic p53 mutation was present - that is, when 
wild-type and mutant p53 were expressed concomitantly, 
a situation frequently found in human cancers. In vitro 
the investigators demonstrate that all the components 
typical of Pin1-catalyzed prolyl isomerization have to be 
present for this epistatic relationship between Pin1 and 
mutant p53: phosphorylation on S/P motifs (S46 and 
S315) in p53 and the phospho-residue binding WW 
domain and the enzymatic PPIase domain in Pin1 were 
required. Functionally, prolyl isomerization of mutant 
but not wild-type p53 rendered p63 dysfunctional and set 
oﬀ   an entirely new transcriptional program that promo-
ted transformation.
Increased Pin1 expression had previously been ob-
served in breast cancer. Th  ese studies had shown that 
high levels of Pin1 tipped the balance between pro-
proliferative signaling and cell cycle checkpoint control 
towards uncontrolled proliferation by aﬀ  ecting,  for 
example, expression of cyclin D1 [9], beta-catenin [14], 
Her2-neu [15] and many other molecules (reviewed in 
[16]). Th  e novel ﬁ  nding by Girardini and colleagues is 
that Pin1-catalyzed prolyl isomerization of mutant p53 
causes a profound qualitative change in an epithelial cell’s 
transcriptional program that could potentially not only 
accelerate but also cause cancer.
One of the striking observations was that Pin1 
appeared to be dispensable for mutant p53-associated 
sarcomas and hematological malignancies, while it was 
absolutely required for the emergence of epithelial 
cancers, which in the case of Li Fraumeni syndrome are 
most frequently breast cancers. Not surprisingly, the 
authors ﬁ  nd that cooperation of mutant p53 with Pin1 
aﬀ  ects breast cancer outcomes and that the combination 
of high Pin1 levels and p53 mutation is a predictor of 
poor prognosis in breast cancer patients.
Th  ese ﬁ  ndings have important clinical implications; if 
feasible, inhibition of Pin1 might be an eﬀ  ective way of 
targeting multiple tumor-promoting genes in breast 
cancer, including a potential reversion of the detrimental 
transcriptional program induced by mutant p53. In p53-
proﬁ   cient cancers, on the other hand, Pin1 inhibition 
might increase genomic instability by hampering its 
interaction with p63. Hence, knowing the p53 status of a 
given cancer would be imperative for plans to use Pin1-
directed inhibition to treat cancer. Th  e conspicuous 
absence of epithelial tumors in Pin1 null mice that carry 
mutant p53 raises the question whether epithelial cells 
have a special requirement for Pin1, which might make 
epithelial cancers particularly vulnerable to Pin1 
inhibition. Finally, Girardini and colleagues’ study raises 
the possibility that there may be more cancer-causing 
mutations in tumor suppressor genes that use Pin1 to 
exert a dominant-negative function.
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